Compare Danaher Corporation (DHR) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Western Alliance Bancorporation — how do they compare? Danaher Corporation trades at $205.74 (market cap $145.83B), while Western Alliance Bancorporation trades at $81.52 (market cap $8.89B). The key difference: Danaher Corporation is far larger — about 16.4× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| DHR | WAL | |
|---|---|---|
Market Cap | $145.83B | $8.89B |
Sector | Health | Financials |
52-Week High | $242.05 | $96.08 |
52-Week Low | $161.91 | $66.70 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Western Alliance Bancorporation (WAL) trades at $81.64, up 1.44% today, with a neutral technical signal and bullish analyst consensus. The stock shows strong fundamentals, including a P/E of 9.2 and net income margin of 25.43%, supported by recent earnings beats. Recent developments include the launch of WA VenueX, an institutional financial platform, and recognition as Arizona's top bank by Forbes in 2026.
The outlook for WAL is positive, with a consensus price target of $93.86 implying 15% upside, driven by revenue growth and profitability. Risks include negative operating cash flow and high interest expenses. Institutional sentiment is mixed, with some firms reducing stakes, but overall analyst ratings remain heavily bullish.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
